Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Clinical Trial FAQs About Us
Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID IM060-0001  |   NCT07115745

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Summary

  • Phase 1
  • Male and Female Gender icon
  • 18+
    Age Range
  • 20
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Systemic lupus erythematosus (SLE) population:.
    1. Diagnosis of SLE based on the 2019 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR).
      1. Participant must be positive for at least one of the following antibodies at screening: anti-nuclear antibody, anti-dsDNA, anti-histone, anti-chromatin or anti-Sm antibody.
        1. Inadequate response or intolerance to steroids and immunosuppressive therapies.
          1. Participants must have active disease at screening.
          2. Inflammatory myopathy (IIM) population:.
            1. Participants meeting the 2017 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria.
              1. Participants must meet criteria for with severe, refractory IIM.
                1. Participants who had inadequate response to steroids and prior immunosuppressive therapies.
                  1. Evidence of active disease.
                  2. Systemic sclerosis (SSc) population:.
                    1. Participant must fulfill the 2013 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) classification criteria for systemic sclerosis.
                      1. Inadequate disease response or intolerance to prior therapies.
                        1. Participants diagnosed with progressive systemic sclerosis including skin disease and/or interstitial lung disease.
                        2. Rheumatoid arthritis (RA) population:.
                          1. Participants with difficult to treat RA.
                            1. Participants with a diagnosis of RA meeting 2010 ACR/EULAR criteria.
                              1. Rheumatoid arthritis disease activity at screening and baseline visit.
                                1. Inadequate disease response or intolerance to standard of care therapy.

                                Exclusion Criteria

                                Exclusion Criteria Icon
                                • All participants:.
                                  1. Any other systemic autoimmune disease.
                                    1. Pregnant or nursing women.
                                      1. Active hepatitis B, C or HIV.
                                        1. Prior history of malignancies.
                                          1. Uncontrolled or active infection.
                                            1. History of certain cardiovascular conditions within 6 months prior to screening.
                                              1. Previous CAR-T cell therapy.
                                                1. Significant lung impairment.
                                                  1. Inadequate organ function.
                                                    1. Active, clinically significant, central nervous system (CNS) disorders.
                                                    2. SLE population:.
                                                      1. Participants who have SLE because of drugs or have other autoimmune diseases along with SLE.
                                                      2. IIM population:.
                                                        1. Participants who have other forms of myopathies other than IIM.
                                                          1. Severe muscle damage.
                                                          2. SSc population:.
                                                            1. People who have high blood pressure in the arteries of the lungs caused by SSc, which needs regular treatment to keep it under control.
                                                              1. Rapidly deteriorating SSc, or history of severe kidney disease.
                                                              2. RA population:.
                                                                1. People who have additional autoimmune diseases along with RA.
                                                                2. Other protocol-defined inclusion/exclusion criteria apply.
                                                                  Additional Information *

                                                                  Treatment Options

                                                                  Study Arms

                                                                  ASSIGNED INTERVENTION

                                                                  Study Arms

                                                                  Experimental: BMS-986515 Administration

                                                                  ASSIGNED INTERVENTION
                                                                  • Genetic: BMS-986515
                                                                  • Drug: Fludarabine, Cyclophosphamide, Tocilizumab
                                                                  Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                                                                  Check Your Eligibility
                                                                  Answer some questions about Your health to see if you may match to this trial
                                                                  Match to a Trial
                                                                  If you are a match, click on the study to see the list of study site locations
                                                                  Select a Study Site Location
                                                                  Select a study site location that is convenient for you
                                                                  Register
                                                                  Provide your contact details for the study site to connect with you.

                                                                  Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you

                                                                  Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you